OTCMKTS:TXSP - Taxus Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.17 +0.01 (+0.32 %)
(As of 01/22/2019 01:22 PM ET)
Previous Close$3.16
Today's Range$3.17 - $3.17
52-Week Range$3.16 - $3.16
Volume100 shs
Average VolumeN/A
Market Capitalization$258.36 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.19
Taxus Pharmaceuticals Holdings, Inc. manages and operates health and wellness stores. Its products include dietary supplements, vitamins, minerals, calcium, fibers, proteins and sport nutrition items. The company was founded on January 2, 2002 and is headquartered in Little Neck, NY.

Receive TXSP News and Ratings via Email

Sign-up to receive the latest news and ratings for TXSP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug stores & proprietary stores
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:TXSP
CUSIPN/A
WebN/A
Phone718-631-1522

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10,000.00
Price / Sales25,835.50

Profitability

Miscellaneous

EmployeesN/A
Market Cap$258.36 million
OptionableNot Optionable

Taxus Pharmaceuticals (OTCMKTS:TXSP) Frequently Asked Questions

What is Taxus Pharmaceuticals' stock symbol?

Taxus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "TXSP."

When is Taxus Pharmaceuticals' next earnings date?

Taxus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, April 19th 2019. View Earnings Estimates for Taxus Pharmaceuticals.

Has Taxus Pharmaceuticals been receiving favorable news coverage?

News coverage about TXSP stock has been trending very positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Taxus Pharmaceuticals earned a news impact score of 3.2 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are some of Taxus Pharmaceuticals' key competitors?

Some companies that are related to Taxus Pharmaceuticals include Diplomat Pharmacy (DPLO), 111 (YI), Petmed Express (PETS), HealthWarehouse.com (HEWA) and Dougherty's Pharmacy (MYDP).

Who are Taxus Pharmaceuticals' key executives?

Taxus Pharmaceuticals' management team includes the folowing people:
  • Jia Yue Zhang, Chairman, President, Chief Executive Officer & CFO

How do I buy shares of Taxus Pharmaceuticals?

Shares of TXSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Taxus Pharmaceuticals' stock price today?

One share of TXSP stock can currently be purchased for approximately $3.17.

How big of a company is Taxus Pharmaceuticals?

Taxus Pharmaceuticals has a market capitalization of $258.36 million and generates $10,000.00 in revenue each year.

How can I contact Taxus Pharmaceuticals?

Taxus Pharmaceuticals' mailing address is 23605 BRADDOCK AVENUE, BELLEROSE NY, 11426. The company can be reached via phone at 718-631-1522.


MarketBeat Community Rating for Taxus Pharmaceuticals (OTCMKTS TXSP)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  74 (Vote Outperform)
Underperform Votes:  118 (Vote Underperform)
Total Votes:  192
MarketBeat's community ratings are surveys of what our community members think about Taxus Pharmaceuticals and other stocks. Vote "Outperform" if you believe TXSP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TXSP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2019 by MarketBeat.com Staff

Featured Article: What is cost of equity?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel